Clinical Trials Logo

Meningioma clinical trials

View clinical trials related to Meningioma.

Filter by:

NCT ID: NCT05278208 Recruiting - Medulloblastoma Clinical Trials

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

Start date: November 21, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in patients with progressive or recurrent High-Grade Central Nervous System (CNS) tumors and meningiomas that demonstrate uptake on DOTATATE PET. The drug will be given intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged 4-12 years (Phase I) or older than 12 yrs (Phase II) to test its safety and efficacy, respectively. Funding Source - FDA OOPD (grant number FD-R-0532-01)

NCT ID: NCT05259332 Recruiting - Meningioma Atypical Clinical Trials

Identification by Transcriptomic Approach of New Prognostic and Predictive Markers in a Cohort of Atypical Meningiomas

TransMenAtyp
Start date: February 25, 2022
Phase:
Study type: Observational

Determine by a transcriptomic approach new prognostic and predictive markers in atypical meningiomas (WHO grade II). Retrospective observational study, on a cohort of 85 atypical meningiomas. Transcriptomic study first, on cryopreserved tumor samples. Then identify, thanks to the transcriptomic study, prognostic and predictive factors (study of the link between the quantity of certain RNA transcripts and progression-free survival). Finally, set up immunohistochemical applications, which can be used routinely by the pathologist.

NCT ID: NCT05254197 Recruiting - Meningioma Clinical Trials

SeOuL cOhort of Brain Tumor MONitoring Study (SOLOMON)

SOLOMON
Start date: January 1, 2001
Phase:
Study type: Observational [Patient Registry]

The registry of this study was subjected to patients who were radiologically diagnosed with a non-malignant brain tumor at Seoul National University Hospital since 2001, and who have had magnetic resonance (MR) re-examination after first MR exam or will be re-examined because it was determined that immediate treatment would not be needed at the first visit to the hospital. In all MRs taken by patients, the date of imaging and the volume of the tumor are measured, and we aim to establish a natural growth history for non-malignant brain tumors.

NCT ID: NCT05230381 Recruiting - Meningioma Clinical Trials

Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection

Start date: June 15, 2022
Phase: N/A
Study type: Interventional

Intra-operative blood loss of huge meningioma resection patients on average was over 1000ml. Intra-operative massive hemorrhage was associated with longer hospital of stay, higher expense, and higher mortality. Previous studies indicated intra-operative tranexamic acid infusion would decrease blood loss for cardiac, trauma and obstetric procedures. However, limited researches focusing on the effect of tranexamic acid in neurosurgery population, with heterogenous pathologies. The purpose of this study was to investigate the effect of tranexamic acid on intra-operative blood loss in patients undergoing huge meningioma resection.

NCT ID: NCT05139277 Recruiting - Glioblastoma Clinical Trials

Evaluation of the CONVIVO System

Start date: June 28, 2022
Phase: N/A
Study type: Interventional

The primary objective of this study is to evaluate the diagnostic performance of the CONVIVO confocal endomicroscope in discriminating between normal and abnormal tissue in vivo during brain tumor surgery. The interpretation of intraoperative images obtained in situ will be tested against conventional histologic evaluation of targeted biopsies from imaged tissue. The study team hypothesize that there will be a high degree of correlation between images obtained with the CONVIVO system and conventional histologic interpretation.

NCT ID: NCT05130866 Recruiting - Clinical trials for Neurofibromatosis Type 2

Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas

POPLAR-NF2
Start date: June 20, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

This is a two-staged, Phase 2/3, randomized, multi-center study to investigate the efficacy and safety of REC-2282 in patients with progressive NF2 mutated meningiomas.

NCT ID: NCT05093751 Completed - Clinical trials for Artificial Intelligence

Automated Segmentation and Volumetry for Meningioma Using Deep Learning

Start date: March 23, 2013
Phase:
Study type: Observational

U-Net-based architectures will be applied to 500 contrast-enhanced axial MR images of different patients from a single institution after manual segmentation of meningioma, of which 50 were used for testing. Tumor volumetry after autosegmentation by trained U-Net-based architecture is final goal.

NCT ID: NCT05081908 Recruiting - Meningioma Atypical Clinical Trials

Multisession Radiosurgery in Residual/Recurrent Grade II Meningiomas.

ATM
Start date: May 17, 2017
Phase: N/A
Study type: Interventional

Fractionated radiosurgery will be delivered to atypical meningioma lesions in salvage setting for patients who present post-surgical residual lesion or develop recurrence.

NCT ID: NCT05028400 Completed - Glioma Clinical Trials

Intraoperative Laser Speckle Contrast Imaging to Assess Blood Flow During Neurosurgery

LSCI-NSURG
Start date: February 1, 2022
Phase: N/A
Study type: Interventional

Cerebral blood flow (CBF) is of paramount importance to human brain function, as the brain relies on a continuous blood supply to meet its energy needs. Blockage of a cerebral blood vessel during neurosurgery, even if transient and short-lived, may result in irreversible brain tissue damage (i.e. stroke) and loss of cortical function, if not identified quickly enough. Laser speckle contrast imaging (LSCI) has been demonstrated to provide the ability to visualize flow in vessels in real time and continuously without the need for contrast agents. In LSCI, the tissue of interest is illuminated with low power laser light at red or near infrared wavelengths and the light reflected from the tissue surface is imaged onto a camera. The resulting images are laser speckle patterns and a computer processes the images to produce speckle contrast images, which are images of the motion within the field of view (ie, blood flow). The purpose of this clinical investigation is to assess the usefulness and accuracy of LSCI compared to ICGA and/or FA during neurovascular surgery. LSCI videos will be recorded automatically intraoperatively in each patient before, during, and after ICGA and/or FA in the same surgical field of view to guarantee comparability of the methods.

NCT ID: NCT05023018 Recruiting - Clinical trials for Residual, Progressive or Recurrent Grade II or III Meningioma

NEO100 and High-Grade Meningioma

Start date: July 1, 2022
Phase: Phase 2
Study type: Interventional

This multi-site, Phase 2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO100 (perillyl alcohol) for the treatment of patients with residual high-grade meningioma following resection surgery, radiographically-confirmed progression of high-grade meningioma or recurrent high-grade meningioma. There will be up to 30 patients enrolled in this study to have 29 evaluable patients. NEO100 will be self-administered four times daily on a 28-day treatment cycle for up to twelve cycles, until disease progression or death, whichever occurs first. Following the completion of cycle twelve, patients receiving benefit will be given the option to continue receiving compassionate use treatment with NEO100.